FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Isoquinolin topics
Isoquinolin
Quinoline Derivatives
Carbon Atoms
Praziquantel
Crystallin
Pharmaceutically Acceptable Salt
Cycloalkyl
Alkyl Group
Sulfonamide
Solifenacin
Cancer Cells
Cancer Cell
Viral Infection
Human Immunodeficiency Virus
Immunodeficiency

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Isoquinolin patents



      
           
This page is updated frequently with new Isoquinolin-related patents. Subscribe to the Isoquinolin RSS feed to automatically get the update: related Isoquinolin RSS feeds.

Subscribe to updates on this page: Isoquinolin RSS RSS

Date/App# patent app List of recent Isoquinolin-related patents
04/17/14
20140107127
 Pyrazinoisoquinoline compounds patent thumbnailnew patent Pyrazinoisoquinoline compounds
This invention relates to novel compounds that are pyrazinoisoquinoline derivatives, and pharmaceutically acceptable salts thereof. More specifically, this invention relates to novel pyrazinoisoquinoline derivatives that are derivatives of praziquantel.
04/17/14
20140107117
 Thienyl- and furanyl-isoquinolinones and methods for using them patent thumbnailnew patent Thienyl- and furanyl-isoquinolinones and methods for using them
The present invention relates to substituted thienyl- and furanyl-isoquinolinones that act, for example, as modulators of poly(adp-ribose) polymerase (parp). The present invention also relates to processes for the preparation of substituted thienyl and furanyl-isoquinolinones and to their use in treating various diseases and disorders..
03/20/14
20140080865
 Salts and solvates of a tetrahydroisoquinoline derivative patent thumbnailSalts and solvates of a tetrahydroisoquinoline derivative
(s)-2-(diphenylacetyl)-1,2,3,4-tetrahydro-6-methoxy-5-(phenylmethoxy)-3-isoquinoline carboxylic acid in substantially pure form is described together with its sodium salt and solvates. Methods for preparing the compound, its sodium salt and its solvates and pharmaceutical compositions comprising them are also described..
02/27/14
20140058100
 Tetrahydroisoquinolin-1-one derivative or salt thereof patent thumbnailTetrahydroisoquinolin-1-one derivative or salt thereof
To provide a pharmaceutical, in particular a compound which can be used as a therapeutic agent for irritable bowel syndrome (ibs). It was found that a tetrahydroisoquinolin-1-one derivative having an amide group at the 4-position or a pharmaceutically acceptable salt thereof has an excellent bombesin 2 (bb2) receptor antagonistic action.
02/13/14
20140046066
 Process for the preparation of dpp-iv inhibitor patent thumbnailProcess for the preparation of dpp-iv inhibitor
Wherein r1, r2 and r3 are each independently hydrogen, halogen, hydroxy, lower alkyl, lower alkoxy or lower alkenyl, wherein lower alkyl, lower alkoxy and lower alkenyl may optionally be substituted by lower alkoxycarbonyl, aryl or heterocyclyl, and the pharmaceutically acceptable salts thereof. The invention also relates to two crystalline forms of (2s,3s,11bs)-1-(2-amino-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a]isoquinolin-3-yl)-4(s)-fluoromethyl-pyrrolidin-2-one dihydrochloride, which are form a and form b and to an amorphous form of said compound..
02/13/14
20140045846
 Isoquinolin-1(2h)-one derivatives as parp-1 inhibitors patent thumbnailIsoquinolin-1(2h)-one derivatives as parp-1 inhibitors
There are provided substituted isoquinolin-1(2h)-one derivatives which selectively inhibit the activity of poly (adp-ribose) polymerase parp-1 with respect to poly (adp-ribose) polymerase parp-2. The compounds of the present invention are therefore useful in treating diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation.
02/06/14
20140038961
 3-ureidoisoquinolin-8-yl derivatives patent thumbnail3-ureidoisoquinolin-8-yl derivatives
These compounds are useful for the prevention or the treatment of bacterial infections.. .
01/23/14
20140024676
 Crystalline forms of a prolyl hydroxylase inhibitor patent thumbnailCrystalline forms of a prolyl hydroxylase inhibitor
The present disclosure relates to crystalline solid forms of [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid, the process of preparing the forms, and pharmaceutical compositions and methods of use thereof.. .
01/23/14
20140024675
 Crystalline forms of a prolyl hydroxylase inhibitor patent thumbnailCrystalline forms of a prolyl hydroxylase inhibitor
The present disclosure relates to crystalline solid forms of [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid, the process of preparing the forms, and pharmaceutical compositions and methods of use thereof.. .
01/16/14
20140018360
 Azaindenoisoquinoline topoisomerase i inhibitors patent thumbnailAzaindenoisoquinoline topoisomerase i inhibitors
The invention described herein pertains to substituted azaindenoisoquinoline compounds, in particular 7-, 8-, 9-, and 10-azaindenoisoquinoline compounds, which are inhibitors of topoisomerase i, processes and intermediates for their syntheses, pharmaceutical compositions of the compounds, and methods of using them in the treatment of cancer.. .
12/26/13
20130345252
Synthesis and use of dual tyrosyl-dna phosphodiesterase i (tdp1)- topoisomerase i (top1) inhibitors
The invention described herein pertains to the synthesis and use of certain n-substituted indenoisoquinoline compounds which inhibit the activity tyrosyl-dna phosphodiesterase i (tdp1) or topoisomerase i (top1) or both, or otherwise demonstrate anticancer activity. Also disclosed are novel n-substituted indenoisoquinoline compounds and pharmaceutical compositions comprising the novel n-substituted indenoisoquinoline compounds..
12/19/13
20130338366
Process for the preparation of pyrido [2,1-a] isoquinoline derivatives comprising optical resolution of an enamine
Wherein rco2− is the conjugate base of the resolving agent.. .
12/19/13
20130338187
Novel 1-(1-oxo-1,2,3,4-tetrahydroisoquinolin-7-yl)urea derivatives as n-formyl peptide receptor like-1 (fprl-1) receptor modulators
The present invention relates to novel 1-(1-oxo-1,2,3,4-tetrahydroisoquinolin-7-yl)urea derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the n-formyl peptide receptor like-1 (fprl-1) receptor.. .
11/28/13
20130317010
Tetrahydroisoquinoline derivative
To provide an excellent agent for preventing or treating dementia and schizophrenia based on serotonin 5-ht5a receptor regulating action, it was found that a tetrahydroisoquinoline derivative characterized by a structure in which an acylguanidino group binds to a n atom of a tetrahydroisoquinoline ring or the like, and a cyclic group binds to an unsaturated ring has a potent 5-ht5a receptor regulating action and an excellent pharmacological action based on the regulating action and also discovered that the tetrahydroisoquinoline derivative is useful as an agent for treating or preventing dementia, schizophrenia, and the like, whereby the present invention has been completed.. .
11/21/13
20130310569
Triazolide based ionic liquids
A method of synthesizing an ionic liquid, includes reacting a 1,2,3-triazole including at least one of a 4-substituent or a 5-substituent with a hydroxide compound having the formula r+oh− in a dehydration reaction, wherein r+ is an ionic liquid cation. R+ is a five-membered heterocyclic cation, an aromatic cation, a sulfonium cation, an ammonium cation, or a phosphonium cation.
11/21/13
20130310370
Drug therapy for preventing or treating glaucoma
There is provided a drug therapy for prevention of glaucoma or prevention or treatment of ocular hypertension, with a potent ocular hypotensive effect and prolonged duration thereof. Disclosed is a combination of (s)-(−)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl-1,4-homopiperazine or a salt thereof, or a solvate thereof, and a prostaglandin for prevention or treatment of glaucoma..
11/14/13
20130303565
Use of a new histamine h4 agonist for the treatment of acute leukemia
A method of treating leukemia by administering an h4 agonist of histamine, 7-amino-4,5,6-triethoxy-3-(5,6,7,8-tetrahydro-4-methoxy-6-methyl-1,3-dioxolo[4,5-g]isoquinolin-5-yl) phthalide (tritoqualine), to a subject is provided.. .
11/14/13
20130303522
Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1
The compounds of formula (i) are derived from perhydroquinoline and perhydroisoquinoline and are useful as active pharmaceutical ingredients for the prophylaxis or treatment of diseases caused by 11-beta-hydroxysteroid dehydrogenase type 1 (11-beta-hsd1) enzyme-associated disorders, such as glaucoma, elevated ocular pressure, metabolic disorders, obesity, metabolic syndrome, dyslipidemia, hypertension, diabetes, atherosclerosis, cushing's syndrome, psoriasis, rheumatoid arthritis, cognitive disorders, alzheimer's disease or neurodegeneration.. .
11/14/13
20130302414
Solubilized capsule formulation of 1,1-dimethylethyl [(1s)-1-carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate
The present disclosure includes various embodiments directed to a solubilized capsule formulation of asunaprevir, 1,1-dimethylethyl[(1s)-1-{[(2s,4r)-4-(7-chloro-4methoxyisoquinolin-1-yloxy)-2-({(1r,2s)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl}carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate, and to methods including asunaprevir.. .
11/07/13
20130296363
Quinoline and isoquinoline derivatives for use as jak modulators
Provided herein are compounds for treatment of jak kinase mediated diseases, including jak2 kinase-, jak3 kinase- or tyk2 kinase-mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions..
10/31/13
20130289275
Process for the preparation of praziquantel
The present disclosure describes a novel, cost-effective process for preparation of a 4-oxo-1,2,3,6,7,11b-hexahydro-4h-pyrazino-[2,1-a]isoquinoline derivatives. Specifically, it discloses a process for the preparation of the anthelmintic drug praziquantel through the use of a novel intermediate, 2-[(2,2-dimethoxyethyl)benzyl amino]-n-phenethylacetamide.
10/31/13
20130289066
Anti-angiogenic compound
A styrylquinoline derivative of structure i or iv or a benzodioxol isoquinoline of structure ii or iii for use in the treatment of an angiogenesis-related disease or disorder. The invention also provides a composition comprising a styrylquinoline derivative of structure i or iv or a benzodioxol isoquinoline of structure ii or iii for use as a medicament..
10/31/13
20130289027
Isoquinoline compounds and methods for treating hiv
Provided are compounds and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and their use for treating viral infections mediated by a member of the retrovirus family of viruses such as the human immunodeficiency virus (hiv).. .
10/24/13
20130281473
Substituted isoquinolinones and quinazolinones
Wherein z is ch2 or n—r4 and x, r1, r2, r4, r6, r7 and n are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of mdm2 and/or mdm4, or variants thereof..
10/17/13
20130274287
Phenyl-tetrahydroisoquinoline derivatives
Wherein r1, r2, r3, r4, r5, r6, r7, r8, r9, r10, r11, r12, a and n are as described herein, compositions including the compounds and methods of using the compounds.. .
10/17/13
20130274286
Nicotinamide phosphoribosyltransferase (nmprtase) inhibitor for glioma therapy
The present invention relates to identification of a compound which inhibits the enzyme nmprtase and glioma cancer cell growth and further used for glioma therapy. Pre-b-cell colony enhancing factor 1 gene (pbef1) encodes nicotinamide phosphoribosyltransferase (nmprtase), which catalyses the rate limiting step in the salvage pathway of nad metabolism in mammalian cells.
10/17/13
20130274269
Novel substituted isoquinoline derivative
The present invention provides a novel isoquinoline-6-sulfonamide derivative that is useful as a medicine. The present invention provides an isoquinoline-6-sulfonamide derivative represented by formula (1), a salt thereof, or a solvate of the derivative or the salt, wherein r1 and r2 each independently represent a hydrogen atom, or the like; r3 and r4 each independently represent a hydrogen atom, an alkyl group, or the like; r5 represents a hydrogen atom, an optionally substituted alkyl group, an optionally substituted alkenyl group, an optionally substituted alkynyl group, an optionally substituted cycloalkyl group, an optionally substituted alkanoyl group, or the like; and a represents a linear or branched alkylene group having 2 to 6 carbon atoms..
10/10/13
20130267557
Combined use of an alpha-adrenergic receptor antagonist and an anti-muscarinic agent
The combined use of (r)-5-(2-{[2-(2-ethoxyphenoxy)ethyl]amino}propyl)-2-methoxybenzene-1-sulfonamide (tamsulosin), or its pharmaceutically acceptable salt, and (1s)-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylic acid (3r)-quinuclidin-3-yl ester (solifenacin), or its pharmaceutically acceptable salt, for the preparation of a medicament for the improvement of lower urinary tract symptoms associated with benign prostatic hyperplasia (luts/bph) with a substantial storage component is provided.. .
10/10/13
20130264553
Materials for organic light emitting diode
Organometallic compounds comprising a phenylquinoline or phenylisoquinoline ligand having the quinoline or isoquinoline linked to the phenyl ring of the phenylquinoline or phenylisoquinoline, respectively, via two carbon atoms. These compounds also comprise a substituent other than hydrogen and deuterium on the quinoline, isoquinoline or linker.
10/10/13
20130264529
Near-infrared absorbing synthetic resin composition
A near-infrared ray absorbing synthetic resin composition containing a bipyrrolo isoquinoline compound represented by the following general formula (1) and a synthetic resin. In the formula, r1 and r2 may be identical with or different from each other, and each represents a hydrogen atom, a halogen atom, an alkyl group having 1 to 20 carbon atoms optionally having substituents, an alkoxy group having 1 to 20 carbon atoms optionally having substituents, an aryl group having 6 to 20 carbon atoms optionally having substituents, an arylalkyl group having 7 to 20 carbon atoms optionally having substituents, or a cycloalkyl group having 5 to 12 carbon atoms optionally having substituents.
09/19/13
20130245268
Enantioselective organic anhydride reactions
Disclosed herein is enantioselective synthetic method comprising reacting an enolisable c4-c50 organic anhydride with a second compound selected from the group consisting of an aldehyde, a ketone, an aldimine, a ketimine or a michael acceptor in the presence of a bifunctional organocatalyst. The reaction may find particular utility in the enantioselective synthesis of medicinally relevant heterocycles, such as dihydroisocoumarins and dihydroisoquinolinones..
09/19/13
20130245036
Crystalline form of an inhibitor of mdm2/4 and p53 interaction
A crystalline form of (s)-1-(4-chloro-phenyl)-7-isopropoxy-6-methoxy-2-(4-{methyl-[4-(4-methyl-3-oxo-piperazin-1-yl)-trans-cyclohexylmethyl]-amino}-phenyl)-1,4-dihydro-2h-isoquinolin-3-one, which is useful in the treatment of a disease or disorder associated with the interaction between p53, or variants thereof, and mdm2 and/or mdm4, or variants thereof, respectively.. .
08/29/13
20130225616
Crystalline form of pyrimidio[6,1-a] isoquinolin-4-one compound
The current invention is directed towards a polymorph of n-{2-[(2e)-2-(mesitylimino)-9,10-dimethoxy-4-oxo-6,7-dihydro-2h-pyrimido[6,1-a]-isoquinolin-3(4h)-yl]ethyl}urea, in the form of a crystalline solid consisting of greater than 99% by weight of n-{2-[(2e)-2-(mesitylimino)-9,10-dimethoxy-4-oxo-6,7-dihydro-2h-pyrimido[6,1-a]-isoquinolin-3(4h)-yl]ethyl}urea, at least 95% in the polymorphic form of a thermodynamically stable polymorph (i) of n-{2-[(2e)-2-(mesitylimino)-9,10-dimethoxy-4-oxo-6,7-dihydro-2h-pyrimido[6,1-a]-isoquinolin-3(4h)-yl]ethyl}urea, wherein said polymorph is determined by single crystal x-ray structural analysis and x-ray powder diffraction pattern.. .
08/29/13
20130224310
Noscapine analogs and their use in treating cancers
Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are noscapine analogs.
08/08/13
20130203749
Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy
The invention relates to pharmaceutical compositions comprising such tetrahydroisoquinolines, and the use of such tetrahydroisoquinolines for therapeutic purposes. The tetrahydroisoquinolines are glyt1 inhibitors..
08/01/13
20130197227
Method of preparing tetrabenazine and dihydrotetrabenazine
The present invention relates to a method for preparing tetrabenazine (tbz) and dihydrotetrabenazine (dtbz), and more specifically to a method for preparing tetrabenazine (tbz) and dihydrotetrabenazine (dtbz) by using simple and short reaction processes of using 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline and 4-methyl-2-(3-(trimethylsilyl)prop-1-ene-2-yl)pentane as starting materials to sequentially perform an alkylation reaction, an aza-prins cyclization reaction in the presence of an oxidant and an oxidation reaction.. .
07/25/13
20130190499
Azaisoquinolinone derivatives as nk3 antagonists
The invention relates to compounds useful in therapy, in particular in the treatment of psychosis, to compositions comprising said compounds, and to methods of treating diseases comprising the administration of said compounds.. .
07/11/13
20130177655
Preventing or treating agent for glaucoma
A preventing or treating agent for glaucoma is provided. This drug has a strong action of reducing intraocular pressure such that the intraocular pressure can be reduced even from the normal intraocular pressure.
07/04/13
20130172343
Derivatives of 1h-isoindol-3-amine, 1h-iso-aza-indol-3amine, 3,4-dihydroisoquinolin-1-amine, and 1,4-dihydroisoquinolin-3-amine as beta-secretase inhibitors
The present invention comprises a new class of compounds useful for the modulation of beta-secretase enzyme activity and for the treatment of beta-secretase mediated diseases, including alzheimer's disease (ad) and related conditions. In one embodiment, the compounds have a general formula i: (i).
06/27/13
20130165437
Novel dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders.
The present invention relates to novel compounds according to formula i that antagonize gpr84, a g-protein-coupled receptor that is involved in inflammatory conditions, and methods for the production of these novel compounds, pharmaceutical compositions comprising these compounds, and methods for the prevention and/or treatment of inflammatory conditions (for example inflammatory bowel diseases (ibd), rheumatoid arthritis, vasculitis, lung diseases (e.g. Chronic obstructive pulmonary disease (copd) and lung interstitial diseases (e.g.
06/13/13
20130150402
Pharmaceutical composition for treating overactive bladder
A pharmaceutical composition comprising (r)-2-(2-aminothiazol-4-yl)-4′-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl}acetanilide or a pharmaceutically acceptable salt thereof and (3r)-quinuclidin-3-yl (1s)-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate or a pharmaceutically acceptable salt thereof, as active ingredients, in particular a pharmaceutical composition for improving various symptoms accompanying overactive bladder, such as urinary urgency, pollakiuria and/or urinary incontinence.. .
06/13/13
20130146848
Novel organic light emitting materials
Novel phosphorescent metal complexes containing 2-phenylisoquinoline ligands with at least two substituents on the isoquinoline ring are provided. The disclosed compounds have low sublimation temperatures that allow for ease of purification and fabrication into a variety of oled devices..
06/06/13
20130144054
Novel production method for isoquinoline derivatives and salts thereof
The present invention provides a method capable of industrially producing a target product, i.e., a compound represented by the aforementioned formula (i) or a salt thereof, which is useful for preventing and treating cerebrovascular disorders such as cerebral infarction, cerebral hemorrhage, subarachnoid hemorrhage, and cerebral edema, particularly for preventing and treating glaucoma, at high yield even on a large scale without imposing a negative impact on the environment. The present invention provides a method for producing a compound represented by formula (i) or a salt thereof, wherein the method comprises a step of reacting a compound represented by formula (iii) or a salt thereof with a compound represented by formula (ii) in the presence of at least one solvent selected from the group consisting of a nitrile solvent, an amide solvent, a sulfoxide solvent, and a urea solvent, and a base..
06/06/13
20130143863
New bicyclic dihydroisoquinoline-1-one derivatives
Wherein r1, r2, r3, r4, r5, r6, a1, a2, a3, a4, a5 and n are as described herein, compositions including the compounds and methods of using the compounds. The compounds are useful, for example, as aldosterone synthase (cyp11b2 or cyp11b1) inhibitors for the treatment or prophylaxis of chronic kidney disease, congestive heart failure, hypertension, primary aldosteronism and cushing syndrome..
05/30/13
20130137874
One-pot preparation of hexahydroisoquinolines from amides
The present invention provides an efficient process for the preparation of hexahydroisoquinolines from amides. In particular, the invention provides a good yielding, one-pot process for the synthesis of hexahydroisoquinolines..
05/30/13
20130137721
6-aminoisoquinoline compounds
6-amino isoquinoline compounds are provided that influence, inhibit or reduce the action of a kinase. Pharmaceutical compositions including therapeutically effective amounts of the 6-aminoisoquinoline compounds and pharmaceutically acceptable carriers are also provided.
05/30/13
20130137718
Process for the preparation of 2-(cyclohexylmethyl)-n--1,2,3,4-tetrahydroisoquinoline-7-sulfonamide
Industrially applicable process for preparing 2-(cyclohexylmethyl)-n-{2-[(2s)-1-methylpyrrolidin-2-yl]ethyl}-1,2,3,4-tetrahydroisoquinoline-7-sulfonamide, and salts thereof.. .
05/23/13
20130131018
Substituted isoquinolines and their use as tubulin polymerization inhibitors
The present invention relates generally to substituted isoquinolines and their use as tubulin polymerization inhibitors. In particular, the invention relates to substituted isoquinolines which possess useful therapeutic activity, use of these compounds in methods of therapy and the manufacture of medicaments as well as compositions containing these compounds..
05/16/13
20130123503
Process for synthesizing substituted isoquinolines
The present disclosure generally relates to a process for synthesizing optionally substituted 1-chloro-4-methoxyisoquinolines. The present disclosure also relates to intermediates useful in this process..
05/16/13
20130123502
Novel process for the preparation of solifenacin succinate
The present invention relates to a process for the preparation of solifenacin succinate by condensing a compound of formula (ivb) with (rs)-3-quinuclidinol, wherein, r represents methyl, ethyl, isopropyl; to produce a diastereomeric mixture of (1s)-3,4-dihydro-1-phenyl-2(1h)-isoquinolinecarboxylic acid (3rs)-1-azabicyclo[2.2.2]oct-3-yl ester, which is treated with succinic acid in a solvent or mixture of solvents to produce optically pure solifenacin succinate, formula (x).. .
05/16/13
20130123302
Process for the preparation of 2-(cyclohexylmethyl)-n--1,2,3,4-tetrahydroisoquinoline-7-sulfonamide
Industrially applicable process for preparing 2-(cyclohexylmethyl)-n-{2-[(2s)-1-methylpyrrolidin-2-yl]ethyl}-1,2,3,4-tetrahydroisoquinoline-7-sulfonamide, and salts thereof.. .
05/09/13
20130115646
Method for measuring glycated hemoglobin
It is to provide a method for measuring glycated hemoglobin in a hemoglobin-containing sample, comprising: reacting glycated hemoglobin in the hemoglobin-containing sample with a proteolytic enzyme in the presence of at least one salt selected from the group consisting of a pyridinium salt, a phosphonium salt, an imidazolium salt, and an isoquinolinium salt; reacting the obtained reaction product with fructosyl peptide oxidase; and measuring the generated hydrogen peroxide. The present invention provides a method for accurately measuring glycated hemoglobin in a hemoglobin-containing sample..
05/02/13
20130109859
Process for the preparation of pyrido[2,1-a] isoquinoline derivatives by catalytic asymmetric hydrogenation of an enamine
Wherein r2, r3, r4 and prot are as defined in the specification.. .
05/02/13
20130109716
N-aminotetrahydroisoquinolines as anti-cancer agents
The compounds herein disclosed are tetrahydroisoquinoline analogs that have modifications on the phenyl rings by introducing groups with various electronic properties. These derivatives of tetrahydroisoquinoline have been shown to have anti-proliferative activity against cells.
05/02/13
20130109715
6-substituted isoquinolines and isoquinolinones
Useful for the treatment and/or prevention of diseases associated with rho-kinase and/or rho-kinase mediated phosphorylation of myosin light chain phosphatase, and compositions containing such compounds.. .
04/18/13
20130096310
Isoquinoline derivative
A compound represented by formula (i) or a pharmaceutically acceptable salt thereof has an effect of inhibiting crth2 and, therefore, is useful as a pharmaceutical.. .
04/18/13
20130096119
Isoquinolin-3-ylurea derivatives
The invention relates to isoquinolin-3-ylurea derivatives of formula (i) wherein r1 represents (c1-c3)alkyl, (c1-c3)haloalkyl or cyclopropyl, r4 represents h and the substituents r2 and r3 and r5 have the meanings disclosed in the specification; and to the salts of such compounds. These compounds are useful for the prevention or the treatment of bacterial infections..
04/04/13
20130085140
Indenoisoquinolinone derivatives, manufacturing method and medical use thereof
Indenoisoquinolinone derivatives (i), the manufacturing method and the medical use thereof, which belong to pharmaceutical chemistry and organic chemistry field, are disclosed. These compounds can be used for treating several medical symptoms related to postmenopausal syndrome, uterine fibers deterioration and aortic smooth muscle cells proliferation, especially er-(+) depend breast cancer.
03/28/13
20130079521
Novel palonosetron salts and processes for preparation and purification thereof
Provided are novel salts of 2-(1-azabicyclo-[2.2.2]oct-3-yl)-2,3,3a,4,5,6-hexahydro-1h-benz[de]isoquinolin-1-one, methods of using such salts, and processes for producing such salts.. .
03/14/13
20130065919
Substituted n-alkyl and n-acyl tetrahydro-isoquinoline derivatives, preparation and therapeutic use thereof
Wherein r, r1, r2, x, m, n and p are as described herein. More specifically, the compounds of this invention are modulators of h3 receptors and are, therefore, useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases modulated by h3 receptors including diseases associated with the central nervous system.
03/07/13
20130060027
Tetrahydroisoquinolines and intermediates therefor
Disclosed are processes for preparing tetrahydroisoquinolines, intermediates useful in the preparation of tetrahydroisoquinolines, processes for preparing such intermediates, and a crystalline form of 6-[(4s)-2-methyl-4-(naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine. Also disclosed are pharmaceutical compositions comprising tetrahydroisoquinolines, methods of using tetrahydroisoquinolines in the treatment of depression and other conditions and methods for obtaining the crystalline form..
03/07/13
20130059882
8-phenylisoquinolines and pharmaceutical composition used in treatment for sepsis
A compound is provided. The compound includes a formula of:.
03/07/13
20130059843
Thiazolyl- and oxazolyl-isoquinolinones and methods for using them
The present invention relates to substituted thiazolyl- and oxazolyl-isoquinolinones that act, for example, as modulators of poly(adp-ribose) polymerase (parp). The present invention also relates to processes for the preparation of substituted thiazolyl- and oxazolyl-isoquinolinones and to their use in treating various diseases and disorders..
03/07/13
20130059838
Substituted n-heteroaryl tetrahydro-isoquinoline derivatives, preparation and therapeutic use thereof
Wherein r, r1, r2, x, m, n and p are as described herein. More specifically, the compounds of this invention are modulators of h3 receptors and are, therefore, useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases modulated by h3 receptors including diseases associated with the central nervous system.
02/14/13
20130041154
Process for producing cisatracurium and associated intermediates
The present invention provides a process of producing cisatracurium compounds, e.g., cisatracurium besylate, from isoquinolinium salts of the structural formula (viia) wherein x− is an anion and r is h or a c1-c6 alkyl, or an activated form of the carboxylic acid with 1,5-pentanediol to form a cisatracurium salt, optionally via an intermediate compound (viii). The cisatracurium compounds can be purified using simple techniques to afford pure cisatracurium besylate without the need for hplc purification..
02/07/13
20130032785
Materials for organic light emitting diode
Organometallic compounds comprising a phenylquinoline or phenylisoquinoline ligand having the quinoline or isoquinoline linked to the phenyl ring of the phenylquinoline or phenylisoquinoline, respectively, via two carbon atoms. These compounds also comprise a substituent other than hydrogen and deuterium on the quinoline, isoquinoline or linker.
01/31/13
20130029997
Pyrazinoisoquinoline compounds
Where the designation (r) indicates that the designated carbon has the (r) stereochemistry; and wherein z1 is hydrogen or fluorine; z2 is hydrogen, deuterium, or fluorine; z3 is deuterium; z4 is fluorine; m is an integer from 0 to 10; n is an integer from 0 to 2; provided that: the sum of m+n does not exceed 10; and when both z1 and z2 are hydrogen, the sum of m+n is greater than 0, and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are beneficially treated by administering an antihelminthic agent, such as praziquantel..
01/17/13
20130018191
Process for the preparation of pyrido [2,1-a] isoquinoline derivatives comprising optical resolution of an enamine
Wherein rco2− is the conjugate base of the resolving agent.. .
01/10/13
20130012711
Substituted phenyl compounds
And to a process for making them. The compounds can be used as intermediates for making 6-substituted-1-(2h)-isoquinolinone derivatives..
01/10/13
20130012479
Polymorphs of 6-(piperidin-4-yloxy)-2h-isoquinolin-1-one hydrochloride
The present invention relates to new crystalline polymorphs of 6-(piperidin-4-yloxy)-2h-isoquinolin-1-one hydrochloride, processes for their preparation and their use, in particular for the preparation of medicaments.. .
01/10/13
20130012444
Crystalline solvates of 6-(piperidin-4-yloxy)-2h-isoquinolin-1-one hydrochloride
The present invention relates to crystalline solvates of 6-(piperidin-4-yloxy)-2h-isoquinolin-1-one hydrochloride, processes for their preparation and the use thereof.. .


Popular terms: [SEARCH]

Isoquinolin topics: Isoquinolin, Quinoline Derivatives, Carbon Atoms, Praziquantel, Crystallin, Pharmaceutically Acceptable Salt, Cycloalkyl, Alkyl Group, Sulfonamide, Solifenacin, Cancer Cells, Cancer Cell, Viral Infection, Human Immunodeficiency Virus, Immunodeficiency

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patents related to Isoquinolin for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Isoquinolin with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         


FreshNews promo



0.3031

3334

1 - 1 - 71